NCI-2024-09407

A Phase 1a/1b Study of the PI3Ka:RAS Breaker BBO-10203 in Subjects with Advanced SolidTumors (The BREAKER-101 Trial)

The BREAKER-101 trial is an early-stage (Phase 1a/1b) research study testing a new drug called BBO-10203 in people with advanced solid tumors that no longer respond to standard treatments. BBO-10203 is designed to block a key cancer growth pathway involving PI3Ka and RAS, which often become overactive or mutated in many types of cancer. When these proteins are overactive, they can send constant “grow and survive” signals to cancer cells, allowing them to multiply uncontrollably. If BBO-10203 is safe and shows signs of working, it could become a breakthrough treatment for cancers that have specific genetic drivers like PI3K or RAS mutations, which are often hard to treat with current drugs.

Advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06625775

Clinical Trial Site: Columbia

To see all available clinical trials click here.